New Stock News | The prospectus of Yingshi Biopharm's IPO has expired.

InxMed Limited (referred to as Ying Shi Biotechnology) submitted its Hong Kong IPO prospectus on August 25, 2025, which expired after 6 months on February 25, 2026. CITIC SEC and Bank of China International were its joint sponsors at the time of submission. According to the earlier prospectus, Ying Shi Biotechnology is a biotech company founded in 2017 in the late clinical stage, dedicated to improving current limited effectiveness in cancer treatment. The company's mission is to address the core challenge of cancer treatment - drug resistance caused by tumor defense. Ying Shi Biotechnology focuses on multiple types of tumors with key signal transduction hubs, especially the FAK and integrin pathways, which play crucial roles in tumor cell survival and lead to the failure of different treatment options. At the same time, Ying Shi Biotechnology targets cancer-associated fibroblasts (CAFs) to dismantle the protective barrier around tumor cells. By targeting key resistant pathways, Ying Shi Biotechnology is reshaping rational drug use in cancer treatment and pioneering innovative treatment frontiers.